There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is
the most common pediatric solid tumor, and accounts for~ 15% of childhood cancer‐related …

Neuroblastoma is a developmental tumor of young children arising from the embryonic
sympathoadrenal lineage of the neural crest. Neuroblastoma is the primary cause of death …

Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic
agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) …

Anaplastic lymphoma kinase (ALK) alterations (activating mutations, amplifications, and
fusions/rearrangements) occur in~ 3.3% of cancers. ALK fusions/rearrangements are …

Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique
features of this type of cancer frequently hamper the process of determining clinical …

Neuroblastoma (NB) is the most common and deadly solid tumour in children. Despite the
development of new treatment options for high-risk NB, over half of patients relapse and five …

The anaplastic lymphoma kinase (ALK) gene plays an important physiologic role in the
development of the brain and can be oncogenically altered in several malignancies …

Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8–
10% of all childhood malignancies. The tumor is characterized by a spectrum of …

High‐risk neuroblastoma (NB) is responsible for a disproportionate number of childhood
deaths due to cancer. One indicator of high‐risk NB is amplification of the neural MYC …

The invasive nature of surgical biopsies deters sequential application, and single biopsies
often fail to reflect tumor dynamics, intratumor heterogeneity and drug sensitivities likely to …